-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Do you want to fully understand the current domestic and foreign targeted immunotherapy drugs for different types of cancer? Which drugs are available domestically and covered by health insurance? Today, the small editor specially took out a collection of accumulated treasures to share with you, that is, according to the classification of cancer categories covering more than 20 cancer-specific immune drugs, involving these drugs listed at home and abroad, NCCN and CSCO guidelines recommended super-drug instructions and medical insurance inclusion and other cases (see table below), in this shared to fight in the front line of the cancer medical workers, patients and their families, with a view to promoting the domestic cancer precision treatment process, with a view to promoting more cancer patients.
Immune checkpoint inhibitor lung cancer breast cancer colorectal cancer stomach cancer gastrointestinal mesothelioma bile tube cancer esophageal cancer pancreatic cancer primary peritoneal cancer neuroendocrine cancer prostate cancer bladder cancer kidney cancer cervical cancer fallopian tube cancer ovarian cancer leukemia lymphoma multiple myeloma Merkel cell carcinoma base cell carcinoma head and neck tumor soft tissue carelli Squamous non-small cell lung cancer adaptation, hepatocellular carcinoma second-line adaptation, esophageal squamous cancer second-line adaptation;
the following drugs are also covered by health insurance: soraphine and gregorinib liver cancer; time and drug names are updated as follows: Pfizer's Dacomitinib is on the market in May 2019, Chinese translation is Dacotinib December 2019 The State Drug Administration announced that the two-targeted joint therapeutic drugs applicable to the treatment of BRAF V600 mutation-positive non-excisible or metastasis melanoma, Novartic Tumor's Darafini (commodity name Tefil) and Qumetini (commodity name Maginen) dual-targeted combined therapy drug have been licensed in China.
to target the new drug Hessele (generic name: Enmetro-Zhu single resistance) on the market! This is the first antibody conjugate drug approved in China (english name Antibody-drug Conjugate, abbreviated as ADC).
in February 2020 Roche's PDL1 monoantimmune in February 2020, with symptoms of small cell lung cancer and hepatocellular carcinoma.
Avelumab is from Merck, Germany, not Merca East.
carelli's single anti-phobias: lung, esophageal and liver cancers.
apatini to increase stomach cancer adaptation.
above, AstraZenecom's "Devaru single resistance" China has been listed, the name corrected to "Dvaliyu single resistance."
source: Global Network of Oncologists